Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
This ingredient has proven soothing, antioxidant and antibacterial action that can play a role in visibly reducing the redness, bumpy texture and general discomfort associated with rosacea
Final research-target dose 2.4 mg + 2.4 mg weekly Titration length ~16 weeks Trial duration 68 weeks (REDEFINE 1 / REDEFINE 2) Route Subcutaneous, once weekly Compound Delivery: 2.4 mg / 2.4 mg Maintenance Pre-blended vials simplify weekly administration to a single injection but lock the ratio at 1:1
Topiramate can interact with carbonic anhydrase inhibitors and other medications affecting acid-base balance
Water, Methylpropanediol, Glycerin, Beta-Glucan, Dimethicone, Titanium Dioxide, Niacinamide, Cyclopentasiloxane, Betaine, Polyglycerin-3, Eclipta Prostrata Leaf Extract, Laminaria Japonica Extract, 1,2-Hexanediol, Sodium Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Sodium Polyacrylate, Ethylhexyl Stearate, Isohexadecane, Panthenol, Dimethiconol, Hydroxyacetophenone, Butylene Glycol, Polysorbate 80, Centella Asiatica Extract, Ficus Carica (Fig) Fruit Extract, Fragrance, Glutathione, Glycyrrhiza Glabra (Licorice) Root Extract, Lactobacillus/Rice Ferment, Sorbitan Oleate, Triethoxycaprylylsilane, Trideceth-6, Hydrogenated Lecithin, Fructooligosaccharides, Hydrogenated Polyisobutene, Squalane, Disodium Edta, Argania Spinosa Kernel Oil, Isononyl Isononanoate, Polyglyceryl-10 Stearate, Amaranthus Caudatus Seed Extract, Butyrospermum Parkii (Shea) Butter, Cetearyl Alcohol, Panax Ginseng Root Extract, Polyglyceryl-2 Dipolyhydroxystearate, Stearic Acid, Ulmus Davidiana Root Extract, Hydrolyzed Hyaluronic Acid, Inulin Lauryl Carbamate, Carbomer, Pearl Powder, Ceramide Np, Polysorbate 20, Disodium Stearoyl Glutamate, Palmitoyl Pentapeptide-4
LR3 IGF-1 binds poorly to IGF binding proteins (IGFBPs), giving it a circulating half-life of roughly 20-30 hours versus minutes for native IGF-1 (Tomas et al., 1993)
What were the Phase 3 TRIUMPH-1 trial results
